In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Colorectal Cancer Screening tests are carried to monitor bowel health of at-risk individuals, typically the elderly, in order to be able to detect and treat colorectal cancer in a timely manner. GlobalData uses proprietary data and analytics to provide a comprehensive report on the colorectal cancer screening tests devices market, including market shares of different players within Norway. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the colorectal cancer screening tests market in Norway was Danaher followed by Aerscher Diagnostics, Thermo Fisher Scientific, Propper Manufacturing, Eiken Chemical, Hemosure, McKesson, QuidelOrtho, Resonac, Alfresa Pharma, Sentinel CH., Medline Industries and Epigenomics.
Colorectal Cancer Screening Tests include Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits, and Other Colorectal Cancer Screening Tests which cover blood-based assays used to screen for colorectal cancer by identifying changes in the methylation status of the Septin 9 gene.
The value of the colorectal cancer screening tests devices market within Norway was expected to be over $0.2m in 2023.
For the latest complete market share analysis of colorectal cancer screening tests device market in Norway, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
